Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amylin/Lilly Byetta Clears FDA As Adjunct Diabetes Therapy; Launch Is June

Executive Summary

Amylin and Lilly will launch the incretin mimetic Byetta (exenatide) for the adjunctive treatment of type 2 diabetes June 1

You may also be interested in...



Lilly Is Reinvesting In Diabetes, Injecting New Life Into Humalog Franchise

Lilly is striving to reenergize its Humalog franchise in 2006 through a pending line extension and an expansion of its insulin production capacity, as the company seeks to rebuild its traditional strength in the diabetes category

Lilly Is Reinvesting In Diabetes, Injecting New Life Into Humalog Franchise

Lilly is striving to reenergize its Humalog franchise in 2006 through a pending line extension and an expansion of its insulin production capacity, as the company seeks to rebuild its traditional strength in the diabetes category

Amylin Agrees To Symlin Marketing Restrictions In Gaining FDA Approval

Amylin has agreed to a ban on direct-to-consumer advertising and other marketing restrictions for its diabetes therapy Symlin (pramlintide) as part of FDA's March 16 approval of the drug

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel